Toll Free: 18008891064
  • Home
  • About Us
  • Product List
    • ONCOLOGY
      • Cytalux (Pofalacianine)
      • Pylarify (Piflufolastat F18)
      • Truseltiq (Infigratinib)
      • Enhertu (Trastuzumab Deruxtecan)
      • Mektovi (Binimetinib)
      • Braftovi (Encorafenib)
      • Libtayo (Cemiplimab-rwlc)
      • Lorbrena (Lorlatinib)
      • Talzenna (Talazoparib)
      • Balversa (Erdafitinib)
      • Piqray (Alpelisib)
      • Alunbrig (Brigatinib)
      • Jemperli (Dostarlimab-gxly)
      • Tepmetko (Tepotinib)
      • COSELA (Trilaciclib)
      • Fotivda (Tivozanib)
      • Rozlytrek (Entrectinib)
      • Tivdak® (tisotumab vedotin-tftv)
      • Ayvakit (Avapritinib)
      • Tazverik (Tazemetostat)
      • Tukysa (Tucatinib)
      • Pemazyre (Pemigatinib)
      • Trodelvy (Sacituzumab govitecan-hziy)
      • Tabrecta (Capmatinib)
      • Retevmo (Selpercatinib)
      • Zepzelca (Lurbinectedin)
      • Gavreto (Pralsetinib)
      • MARGENZATM (margetuximab-cmkb)
      • Orgovyx (relugolix)
      • DANYELZA (naxitamab-gqgk)
      • ZEJULA (Niraparib)
      • VERZENIO (Abemaciclib)
      • TECENTRIQ (Atezolizumab)
      • NERLYNX (Neratinib)
      • Yervoy
      • CAPRELSA (Vandetnib)
      • CELSENTRI (Maraviroc)
      • CIDOFOVIR (Visitide)
      • IBRANCE (Palbociclib Capsules)
      • COMETRIQ (Cabozantinib)
      • CYRAMZA (Ramucirumab Injection)
      • DABRAFENIB (Tafinlar)
      • ENTEREG (Almiopan Capsule)
      • ERIVEDGE (Vismodegib Tablet)
      • LYNPARZA (Olaparib)
      • Qinlock (Ripretinib)
      • MEKINIST (Trametnib Tablet)
      • Mitotane (Lysodren)
      • NAVELBINE ORAL (Vinorelbine)
      • TEYSUNO (Tegafur)
      • ZELBORAF (Vemurafenib Tablet)
      • Zepzelca (Lurbinectedin)
      • ZYDELIG (Idelalisib)
    • HEMATOLOGY
      • Rezurock (Belumosudil)
      • Empaveli (Pegcetacoplan)
      • Idhifa (Enasidenib)
      • Besponsa (Inotuzumab Ozogamicin)
      • Tibsovo (Ivosidenib)
      • Poteligeo (Mogamulizumab-kpkc)
      • Xospata (Gilteritinib)
      • Asparlas (Calaspargase pegol-mknl)
      • Polivy (Polatuzumab Vedotin-piiqa
      • Reblozyl (Luspatercept–aamt)
      • Ukoniq (Umbralisib)
      • Pepaxto (Melphalan Flufenamide)
      • Zynlonta (Loncastuximab Tesirine-lpyl)
      • Rylaze
      • Exkivity (Mobocertinib)
      • SCEMBLIX®(Asciminib)
      • Besremi (Ropeginterferon alfa-2b-njft)
      • SARCLISA® (isatuximab-irfc)
      • Inqovi (decitabine and cedazuridine)
      • Blenrep (Belantamab Mafodotin-blmf)
      • Monjuvi (Tafasitamab-cxix)
      • TAFINLAR (Dabrafenib)
      • CALQUENCE (Acalabrutinib)
      • MYLOTARG Gemtuzumab
      • Aliqopa(Copanlisib)
      • Brentuximab Vedotin
      • AGRYLIN (Anagrelide Hydrochloride)
      • ATRIANCE (Nelarabine)
      • BLINCYTO (Blinatumomab)
      • ONCASPAR (Pegaspargase)
      • ERWINAZE (Asparaginase Erwinia Chrysanthemi)
      • FOLOTYN (Pralatrexate)
      • TREOSULFAN (Treosulfan)
      • Ponatinib
      • NPLATE (Romiplostim)
      • KYPROLIS (Carfilzomib)
      • MABCAMPATH (Alemtuzumab)
      • VENCLEXTA (Venetoclax)
      • SOLIRIS (eculizumab)
      • SYNRIBO (Omacetaxine Mepesuccinate)
      • ALKERAN (Melphalan)
      • FARYDAK (Panobinostat)
      • BOSULIF (Bosutinib)
      • ELDISINE (Vindesine Sulphate)
      • Ixazomib Citrate
      • TEPADINA (Thiotepa)
      • ZOLINZA (Vorinostat)
    • Nephrology
      • Ultomiris (Ravulizumab)
    • GASTROENTROLOGY
      • VOSEVI (Sofosbuvir, Velpatasvir, And Voxilaprevir)
      • OLYSIO (SIMEPREVIR)
      • SYPRINE (Trientine HCL)
    • NEUROLOGY
      • Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
      • Qelbree (Viloxazine)
      • Lybalvi (Olanzapine and Samidorphan)
      • Aduhelm (aducanumab-avwa)
      • NUEDEXTA (Dextromethorphan Hydrobromide)
      • ILARIS (Canakinumab)
      • GLIOLAN (Aminolevulinic acid hydrochloride)
      • STELARA (Ustekinumab)
      • HUMIRA (Adalimumab)
    • IMMUNOLOGY
      • Ocrevus (Ocrelizumab)
      • Skyrizi (Risankizumab-rzaa)
      • PONVORY®(ponesimod)
      • Zeposia (Ozanimod)
      • SILIQ (Brodalumab)
      • TREMFYA (Guselkumab)
    • RARE DISEASES
      • Nulibry (Fosdenopterin)
      • Welireg (Belzutifan)
      • Xiaflex (Collagenase Clostridium Histolyticum)
      • Mepsevii (Vestronidase alfa-vjbk)
      • Symdeko (Tezacaftor/Ivacaftor & Ivacaftor)
      • Palynziq (Pegvaliase-pqpz)
      • Onpattro (Patisiran)
      • Galafold (Migalastat)
      • Diacomit (Stiripentol)
      • Takhzyro (Lanadelumab)
      • Orfadin (Nitisinone)
      • Trikafta (elexacaftor, tezacaftor and ivacaftor)
      • Spinraza (Nusinersen)
      • Amondys 45 (Casimersen)
      • Voxzogo (Vosoritide)
      • Tepezza (Teprotumumab-trbw)
      • Isturisa (Osilodrostat)
      • Koselugo (Selumetinib)
      • VILTEPSO (Viltolarsen)
      • XERMELO (Telotristat)
      • BRINUERA(Cerliponase alfa)
      • MEPSEVII (Vestronidase)
      • PARSABIV (Etelcalcetide)
      • RADICAVA (Edaravone)
      • RHOPRESSA (Netarsudil)
    • Cardio
      • Vyndaqel (tafamidis meglumine)
    • MISC.
      • Brexafemme (Ibrexafungerp)
      • Qulipta Atogepant
      • Zemdri (Plazomicin)
      • Epidiolex (Cannabidiol)
      • ZAVICEFTA (Avibactum + Ceftazidime)
      • BAXDELA (Delafloxacin)
      • BEVYXXA (Betrixaban)
      • FASENRA (Benralizumab)
      • FIRAZYR (Icatibant)
      • KEVZARA(Sarilumab)
      • TRULANCE (Plecanatide)
      • VIVITROL (Naltrexone)
      • XADAGO (Safinamide)
      • Foscavir (Foscarnet sodium injection)
      • Anakinra (Kineret)
      • PADCEV (Enfortumab Vedotin-ejfv)
      • Lonsurf (Trifluridine/Tipiracil)
      • Dantrium IV (Dantrolene Sodium)
  • Blog
  • Contact Us

Triple Negative Breast Cancer (TNBC)

Triple-negative breast cancer or TNBC is a type of breast cancer that does not have any of the receptors that are typically found in breast cancer. As aggressive cancer, TNBC grows and progresses quickly. It’s more likely than other breast cancers to come back. TNBC has limited treatment options, which tends to make for a poorer prognosis. This can be treated with surgery, chemo, radiation therapy, immunotherapy and newer breast cancer treatment options through clinical trials. 

About Triple-negative Breast Cancer (TNBC):

Estimated 10 % to 15 % of all breast cancers are triple-negative. Its name signifies that cancer cells have tested negative for 3 molecular components of breast cancer cells; receptors for the hormones estrogen and progesterone, and the protein known as a human epidermal growth factor, or HER2. Triple-negative breast cancer (TNBC) is defined as progesterone receptor-negative, estrogen receptor-negative (ER-) and, HER2-negative.

  • Certain women are more likely to be diagnosed with triple-negative breast cancer (TNBC):
  • Black women
  • Women aged younger than 40 years
  • Women with a BRCA1 gene mutation

Note: Triple-negative breast cancer (TNBC) may also be more common in Hispanic women.

Signs and Symptoms of Triple-negative Breast Cancer (TNBC):

The signs and symptoms of TNBC are the same as with all other breast cancers. The disease may present as a lump, which is hard, painless and irregular, but can also be soft, round, and painful. Other signs and symptoms include:

  • Breast swelling
  • Discharge from a nipple
  • A nipple that turns inward
  • Swelling or a lump under the arm or on the collarbone
  • Dimpling of the skin, occasionally reminiscent of an orange peel
  • Skin changes on the breast or nipple, including redness, dryness, thickening, or flaking

Diagnosis of Triple-negative Breast Cancer (TNBC):

Imaging tests are typically the first tests done:

Mammography: This is the most commonly used screening tool for breast cancer. It uses X-rays to capture images of the breast and can uncover tumors that may be tiny to feel.

MRI (Magnetic Resonance Imaging): This uses a magnet, radio waves and a computer to make detailed images of the breast with high resolution than a mammogram offers.

The next step is a biopsy to eliminate a sample of suspicious cells from the breast to examine them. Techniques include:

  • Fine-needle aspiration biopsy
  • Core needle biopsy
  • Surgical biopsy

Suitable biopsy for you typically depends on factors such as the size of the tumor and its location. A biopsy of underarm lymph nodes is done at the same time to check if any cancer is there.

Triple-negative Breast Cancer (TNBC) Treatment:

For triple-negative cancers, primary types of cancer-fighting treatment are significant options. These typically include:

  • Surgery
  • Chemotherapy
  • Radiation

Surgery may be a breast-conserving type, such as a lumpectomy, or mastectomy (removal of complete breast tissue from the breast), on behalf of the tumor’s characteristics. In both cases, surrounding lymph nodes would be eliminated and examined to check if cancer has progressed.

Chemotherapy may be given prior to surgery for shrinking the tumor or following surgery to help prevent cancer recurrence. If someone is a candidate for oral chemotherapy they may be given a drug known as capecitabine for 18-24 weeks, to destroy cancer cells. Chemotherapy for breast cancer appears to have a bit more benefit for those with triple-negative breast cancer than it does for those who have HR-positive cancer.

Radiation therapy for breast cancer involves targeting the breast with high-intensity radiation to kill any unhealthy cells that might have been skipped/missed.

The additional treatment options for the more advanced stage of breast cancer may include PARP inhibitors, advanced forms of chemotherapy, platinum-based chemotherapy medicines (carboplatin and cisplatin), and Immunotherapy.

Immunotherapy medicines known as checkpoint inhibitors can help the immune system resist or even inhibit the progression of cancerous cells. These include the monoclonal antibody medinal products pembrolizumab and atezolizumab.

  • In combination with chemotherapy, medicine atezolizumab is considered a first-line treatment for a type of triple-negative breast cancer (TNBC) that makes a protein named PD-L1, found in approximately 20 % of these cancers.
  • Pembrolizumab is primarily used for recurrent tumors that make PD-L1 that can’t be surgically eliminated or when cancer has progressed.

Metastatic breast cancer may also be treated with an antibody-drug conjugate (ADC)—a medicine that links a chemical toxic to unhealthy/cancerous cells with an antibody that targets a receptor that helps cancer grow. There is an FDA-approved medication named Sacituzumab govitecan-hziy (Trodelvy) for those whose triple-negative breast cancer (TNBC) has metastasized and who previously received two other cancer therapies.

Survival Rates for Triple-negative Breast Cancer:

The survival rates (SR) are averages determined by what’s happened in the past. As research and cancer treatment evolves, the outlook may enhance. The 5-year survival rate for someone with localized triple negative breast cancer (TNBC), cancer that has not progressed beyond the breast, is 91 % (91 % as likely as someone without cancer to survive during the 5-year period). For cancer that has progressed into nearby lymph nodes or nearby areas, the 5-year survival rate is 65 %. For cancer that has progressed into the bones, lungs, or liver, the survival is 11 %.

Get in Touch with us for TNBC Treatment Medicines: 

Patients, physicians, and hospitals can authentically access TNBC treatment medicines from Indian Pharma Network. Make an inquiry and we will help you calculate the total price to buy Trodevy 180 mg injection online and have it delivered where you live. We`re well known in the healthcare industry for our quality service, vast industry experience, market credentials, on-time delivery, and good financial standing. Our tie-ups and sourcing from the reputed brands enable us to offer the best prices for TNBC medications. 

  • Posted by admin
  • On January 31, 2023
  • 0 Comments
  • 0 likes
Tags: breast cancer causes, breast cancer symptoms, Triple Negative Breast Cancer, Triple Negative Breast Cancer treatment, trodelvy 180 mg injection, Trodelvy 180 mg price in India, trodelvy 180 mg vial, TRODELVY injection 180 mg

0 Comments

Leave Reply Cancel reply

You must be logged in to post a comment.

Archives
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
Categories
  • Achondroplasia (1)
  • acute lymphocytic leukemia (4)
  • Adrenal Cancer (1)
  • adrenal gland (1)
  • Bladder Cancer (3)
  • blood cancer (2)
  • Breast Cancer (9)
  • Chronic Lymphocytic Leukemia (2)
  • CMV (1)
  • Crohn’s disease (1)
  • DLBCL (1)
  • Drug & Cosmetic Act (1)
  • Enhertu (2)
  • hereditary tyrosinemia (1)
  • Hodgkin Lymphoma (4)
  • leukaemia (2)
  • Metastatic Breast Cancer (3)
  • metastatic colorectal cancer (2)
  • name patient import (1)
  • named patient program india (2)
  • NSCLC (1)
  • PNH (2)
  • RETEVMO (1)
  • rheumatoid arthritis (1)
  • Stomach Gastric Cancer (1)
  • T-cell Acute Lymphoblastic Leukaemia (1)
  • thyroid carcinoma (2)
  • Uncategorized (1)
Archives
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
Popular Posts
  • Understanding Rheumatoid Arthritis (RA)December 20, 2021
  • Nelarabine : Drug Information for PatientsOctober 29, 2021
  • Blincyto Treatment for Acute Lymphoblastic LeukemiaDecember 3, 2021
Photo Stream

Nelarabine : Drug Information for Patients

Previous thumb

Hodgkin's Lymphoma Treatment

Next thumb
Scroll

Indian Pharma Network helps in accessing new products in India. These products are launched and approved recently in USA or Europe but yet to be approved in India. We help in accessing these new launches through named patient import.

Quick Links
  • Home
  • About Us
  • Blog
  • Contact us
About Us

Indian Pharma Network facilitates patients connecting with genuine pharmaceutical suppliers, wholesalers and dealers.

Indian Pharma Network.
info@indianpharmanetwork.in
Corporate Office
Indian Pharma Network.
905 – 9th Floor, I-Thum Business Park,
Tower A, Plot no. A-40, Unit no. 5,
Sector-62, Noida 201301,
info@indianpharmanetwork.in
  • +91 9310090915

  • @2022 All Right Reserved indianpharmanetwork

    WhatsApp us

    • Home
    • About Us
    • Product List
      • ONCOLOGY
        • Cytalux (Pofalacianine)
        • Pylarify (Piflufolastat F18)
        • Truseltiq (Infigratinib)
        • Enhertu (Trastuzumab Deruxtecan)
        • Mektovi (Binimetinib)
        • Braftovi (Encorafenib)
        • Libtayo (Cemiplimab-rwlc)
        • Lorbrena (Lorlatinib)
        • Talzenna (Talazoparib)
        • Balversa (Erdafitinib)
        • Piqray (Alpelisib)
        • Alunbrig (Brigatinib)
        • Jemperli (Dostarlimab-gxly)
        • Tepmetko (Tepotinib)
        • COSELA (Trilaciclib)
        • Fotivda (Tivozanib)
        • Rozlytrek (Entrectinib)
        • Tivdak® (tisotumab vedotin-tftv)
        • Ayvakit (Avapritinib)
        • Tazverik (Tazemetostat)
        • Tukysa (Tucatinib)
        • Pemazyre (Pemigatinib)
        • Trodelvy (Sacituzumab govitecan-hziy)
        • Tabrecta (Capmatinib)
        • Retevmo (Selpercatinib)
        • Zepzelca (Lurbinectedin)
        • Gavreto (Pralsetinib)
        • MARGENZATM (margetuximab-cmkb)
        • Orgovyx (relugolix)
        • DANYELZA (naxitamab-gqgk)
        • ZEJULA (Niraparib)
        • VERZENIO (Abemaciclib)
        • TECENTRIQ (Atezolizumab)
        • NERLYNX (Neratinib)
        • Yervoy
        • CAPRELSA (Vandetnib)
        • CELSENTRI (Maraviroc)
        • CIDOFOVIR (Visitide)
        • IBRANCE (Palbociclib Capsules)
        • COMETRIQ (Cabozantinib)
        • CYRAMZA (Ramucirumab Injection)
        • DABRAFENIB (Tafinlar)
        • ENTEREG (Almiopan Capsule)
        • ERIVEDGE (Vismodegib Tablet)
        • LYNPARZA (Olaparib)
        • Qinlock (Ripretinib)
        • MEKINIST (Trametnib Tablet)
        • Mitotane (Lysodren)
        • NAVELBINE ORAL (Vinorelbine)
        • TEYSUNO (Tegafur)
        • ZELBORAF (Vemurafenib Tablet)
        • Zepzelca (Lurbinectedin)
        • ZYDELIG (Idelalisib)
      • HEMATOLOGY
        • Rezurock (Belumosudil)
        • Empaveli (Pegcetacoplan)
        • Idhifa (Enasidenib)
        • Besponsa (Inotuzumab Ozogamicin)
        • Tibsovo (Ivosidenib)
        • Poteligeo (Mogamulizumab-kpkc)
        • Xospata (Gilteritinib)
        • Asparlas (Calaspargase pegol-mknl)
        • Polivy (Polatuzumab Vedotin-piiqa
        • Reblozyl (Luspatercept–aamt)
        • Ukoniq (Umbralisib)
        • Pepaxto (Melphalan Flufenamide)
        • Zynlonta (Loncastuximab Tesirine-lpyl)
        • Rylaze
        • Exkivity (Mobocertinib)
        • SCEMBLIX®(Asciminib)
        • Besremi (Ropeginterferon alfa-2b-njft)
        • SARCLISA® (isatuximab-irfc)
        • Inqovi (decitabine and cedazuridine)
        • Blenrep (Belantamab Mafodotin-blmf)
        • Monjuvi (Tafasitamab-cxix)
        • TAFINLAR (Dabrafenib)
        • CALQUENCE (Acalabrutinib)
        • MYLOTARG Gemtuzumab
        • Aliqopa(Copanlisib)
        • Brentuximab Vedotin
        • AGRYLIN (Anagrelide Hydrochloride)
        • ATRIANCE (Nelarabine)
        • BLINCYTO (Blinatumomab)
        • ONCASPAR (Pegaspargase)
        • ERWINAZE (Asparaginase Erwinia Chrysanthemi)
        • FOLOTYN (Pralatrexate)
        • TREOSULFAN (Treosulfan)
        • Ponatinib
        • NPLATE (Romiplostim)
        • KYPROLIS (Carfilzomib)
        • MABCAMPATH (Alemtuzumab)
        • VENCLEXTA (Venetoclax)
        • SOLIRIS (eculizumab)
        • SYNRIBO (Omacetaxine Mepesuccinate)
        • ALKERAN (Melphalan)
        • FARYDAK (Panobinostat)
        • BOSULIF (Bosutinib)
        • ELDISINE (Vindesine Sulphate)
        • Ixazomib Citrate
        • TEPADINA (Thiotepa)
        • ZOLINZA (Vorinostat)
      • Nephrology
        • Ultomiris (Ravulizumab)
      • GASTROENTROLOGY
        • VOSEVI (Sofosbuvir, Velpatasvir, And Voxilaprevir)
        • OLYSIO (SIMEPREVIR)
        • SYPRINE (Trientine HCL)
      • NEUROLOGY
        • Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
        • Qelbree (Viloxazine)
        • Lybalvi (Olanzapine and Samidorphan)
        • Aduhelm (aducanumab-avwa)
        • NUEDEXTA (Dextromethorphan Hydrobromide)
        • ILARIS (Canakinumab)
        • GLIOLAN (Aminolevulinic acid hydrochloride)
        • STELARA (Ustekinumab)
        • HUMIRA (Adalimumab)
      • IMMUNOLOGY
        • Ocrevus (Ocrelizumab)
        • Skyrizi (Risankizumab-rzaa)
        • PONVORY®(ponesimod)
        • Zeposia (Ozanimod)
        • SILIQ (Brodalumab)
        • TREMFYA (Guselkumab)
      • RARE DISEASES
        • Nulibry (Fosdenopterin)
        • Welireg (Belzutifan)
        • Xiaflex (Collagenase Clostridium Histolyticum)
        • Mepsevii (Vestronidase alfa-vjbk)
        • Symdeko (Tezacaftor/Ivacaftor & Ivacaftor)
        • Palynziq (Pegvaliase-pqpz)
        • Onpattro (Patisiran)
        • Galafold (Migalastat)
        • Diacomit (Stiripentol)
        • Takhzyro (Lanadelumab)
        • Orfadin (Nitisinone)
        • Trikafta (elexacaftor, tezacaftor and ivacaftor)
        • Spinraza (Nusinersen)
        • Amondys 45 (Casimersen)
        • Voxzogo (Vosoritide)
        • Tepezza (Teprotumumab-trbw)
        • Isturisa (Osilodrostat)
        • Koselugo (Selumetinib)
        • VILTEPSO (Viltolarsen)
        • XERMELO (Telotristat)
        • BRINUERA(Cerliponase alfa)
        • MEPSEVII (Vestronidase)
        • PARSABIV (Etelcalcetide)
        • RADICAVA (Edaravone)
        • RHOPRESSA (Netarsudil)
      • Cardio
        • Vyndaqel (tafamidis meglumine)
      • MISC.
        • Brexafemme (Ibrexafungerp)
        • Qulipta Atogepant
        • Zemdri (Plazomicin)
        • Epidiolex (Cannabidiol)
        • ZAVICEFTA (Avibactum + Ceftazidime)
        • BAXDELA (Delafloxacin)
        • BEVYXXA (Betrixaban)
        • FASENRA (Benralizumab)
        • FIRAZYR (Icatibant)
        • KEVZARA(Sarilumab)
        • TRULANCE (Plecanatide)
        • VIVITROL (Naltrexone)
        • XADAGO (Safinamide)
        • Foscavir (Foscarnet sodium injection)
        • Anakinra (Kineret)
        • PADCEV (Enfortumab Vedotin-ejfv)
        • Lonsurf (Trifluridine/Tipiracil)
        • Dantrium IV (Dantrolene Sodium)
    • Blog
    • Contact Us